Dolutegravir Resistance in Malawi's National HIV Treatment Program. (5th April 2022)

• Record Type: Journal Article
• Authors: van Oosterhout, Joep J; Chipungu, Chifundo; Nkhoma, Lyse; Kanise, Hope; Hosseinipour, Mina C; Sagno, Jean Babtiste; Simon, Katherine; Cox, Carrie; Hoffman, Risa; Steegen, Kim; Matola, Bilaal W; Phiri, Sam; Jahn, Andreas; Nyirenda, Rose; Heller, Tom
• Is Part Of: Open forum infectious diseases. Volume 9:Number 5(2022)
• Publication Date: 2022-04-05
• Subjects: Africa -- antiretroviral therapy -- dolutegravir -- HIV -- Malawi -- resistance; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac148
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.